Publication Date
4-1-2023
Journal
Clinical Gastroenterology and Hepatology
DOI
10.1016/j.cgh.2022.02.056
PMID
35276326
PMCID
PMC9452600
PubMedCentral® Posted Date
4-1-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Tenofovir, Carcinoma, Hepatocellular, Hepatitis B, Chronic, Hepatitis B virus, Antiviral Agents, Cohort Studies, Retrospective Studies, Liver Neoplasms, Treatment Outcome
Abstract
The comparative effectiveness of tenofovir (TDF) versus entecavir (ETV) in reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (HBV) remains unclear. Data from a retrospective Korean cohort study published by Choi et al. initially suggested lower than expected incidence of HCC in patients on long-term TDF. However, additional studies from Korea did not show a statistically significant difference in HCC incidence rate between TDF and ETV groups, and subsequent studies reported mixed results ranging from no association or a slight advantage for TDF4. Most of these studies examined Asian patients from Korea, Taiwan, and China.
The largest U.S. study examined a cohort including 2193 ETV-treated and 1094 TDF-treated patients in the national Department of Veterans Affairs (VA) database and reported no significant association between the type of HBV treatment of HCC risk. However, this study was limited by the possibility of HCC misclassification, incomplete measurement of exposure to medications and adjustment for confounders.,
Included in
Digestive System Diseases Commons, Gastroenterology Commons, Hepatology Commons, Medical Sciences Commons, Oncology Commons